Literature DB >> 21431428

Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy.

Swasti Chaturvedi1, Leonardo Brandao, Denis Geary, Christoph Licht.   

Abstract

Antiphospholipid syndrome is a multisystem auto-immune disorder characterized by thrombotic events and the presence of circulating antiphospholipid antibodies. Large vessel involvement in the form of thrombosis/stenosis and thrombotic microangiopathy is a commonly described renal finding. However, non-thrombotic glomerulopathies are increasingly being recognized in patients with antiphospholipid syndrome. We report a rare occurrence of both renal vein thrombosis and membranous nephropathy in a previously healthy adolescent male. Investigations revealed persistently positive antiphospholipid antibodies in the absence of an underlying systemic autoimmune disorder or malignancy. Our patient responded favourably to anti-proteinuric therapy and anticoagulation with complete resolution of proteinuria and a nearly occlusive thrombus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431428     DOI: 10.1007/s00467-011-1787-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  34 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing.

Authors:  Emmanuel J Favaloro; Roger Silvestrini
Journal:  Am J Clin Pathol       Date:  2002-10       Impact factor: 2.493

3.  Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice.

Authors:  Y Levy; L Ziporen; B Gilburd; J George; S Polak-Charcon; H Amital; J Cledes; P Youinou; Y Shoenfeld
Journal:  Hum Antibodies Hybridomas       Date:  1996

4.  Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial.

Authors:  Min Chen; Hang Li; Xia-Yu Li; Fu-Ming Lu; Zhao-Hui Ni; Fei-Fei Xu; Xue-Wang Li; Jiang-Hua Chen; Hai-Yan Wang
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

Review 5.  Antiphospholipid syndrome and the kidneys.

Authors:  Imad Uthman; Munther Khamashta
Journal:  Semin Arthritis Rheum       Date:  2006-06       Impact factor: 5.532

6.  The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party.

Authors:  J S Cameron; M J Healy; D Adu
Journal:  Q J Med       Date:  1990-02

7.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

8.  End-stage renal disease from glomerulonephritis associated with anti-phospholipid syndrome.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2004-05-06       Impact factor: 3.714

9.  Outcome of primary antiphospholipid syndrome in childhood.

Authors:  M Gattorno; F Falcini; A Ravelli; F Zulian; A Buoncompagni; G Martini; M Resti; P Picco; A Martini
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Deep venous thrombosis in a child with nephrotic syndrome associated with a circulating anticoagulant and acquired protein S deficiency.

Authors:  F Garbrecht; S Gardner; V Johnson; E Grabowski
Journal:  Am J Pediatr Hematol Oncol       Date:  1991
View more
  1 in total

Review 1.  Renal involvement in antiphospholipid syndrome.

Authors:  Savino Sciascia; Maria José Cuadrado; Munther Khamashta; Dario Roccatello
Journal:  Nat Rev Nephrol       Date:  2014-03-18       Impact factor: 28.314

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.